Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at .WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows:
馬薩諸塞州沃爾瑟姆，2024年11月25日 /PRNewswire/ -- Spyre Therapeutics, Inc. (納斯達克: SYRE) 是一家臨床階段的生物技術公司，利用一流的抗體工程、合理的治療組合和精準醫療方法，旨在提高治療炎症性腸病（"IBD"）的療效和便利性，今天宣佈將參加第七屆evercore ISI HealthCONx會議的爐邊聊天和投資者會議。爐邊聊天的詳細信息如下：
- Tuesday, December 3, 2024, at 7:30 a.m. Eastern time
- 2024年12月3日，東部時間上午7:30
To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay following the end of the conference.
要訪問此網絡直播，請訪問Spyre網站投資者部分的"活動與演示"頁面，網址爲ir.spyre.com。會議結束後，將提供網絡直播的檔案以供重播。
About Spyre Therapeutics
關於Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at .
Spyre Therapeutics是一家臨床階段的生物技術公司，旨在通過結合最先進的抗體工程、合理的治療組合和精密的醫學方法，創建下一代炎症性腸病（IBD）產品。Spyre的產品線包括針對α4β7、TL1A和IL-23的延長半衰期抗體。了解更多信息，請訪問Spyre的網站。
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
在社交媒體上關注Spyre Therapeutics: @spyretx和LinkedIn
SOURCE Spyre Therapeutics, Inc.
資料來源：Spyre Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。